Conclusions:
The VIABAHN stent graft is a safe, effective, and durable device for treating cephalic arch stenosis when venoplasty fails.
Summary: To determine the effectiveness of the VIABAHN stent graft to treat cephalic arch stenosis in patients with dysfunctional brachiocephalic arteriovenous fistulas after inadequate venoplasty. Between 2012 and 2015, patients with failed venoplasty of symptomatic cephalic arch stenosis received a VIABAHN stent graft and are evaluated this retrospective study. Follow-up venography was performed at approximately 3, 6, and 12 months. Data were retrospectively analyzed with patency estimated using Kaplan-Meier and log-rank methodology. There were 39 patients included. Technical and clinical success was 100%. Primary target lesion patency was 85% (95% confidence interval [CI] , 69%-93%), 67% (95% CI, 50%-80%), and 42% (95% CI, 25%-57%) at 3, 6, and 12 months. There was no significant difference in patency with regard to sex or age (P ¼ .8 and P ¼ .6, respectively). Primary assisted patency was 95% (95% CI, 82%-99%) at 3, 6, and 12 months. Access circuit primary patency was 85% (95% CI, 69%-93%), 67% (95% CI, 50%-80%), and 42% (95% CI, 25%-57%) at 3, 6, and 12 months. There was no significant difference in patency between patients with the stent graft as the first treatment episode in the cephalic arch and those that had previous intervention at this site (P ¼ .98). There were 48 repeat venoplasty procedures performed in the cephalic arch to maintain patency, including seven repeat VIABAHN insertions. No complications were encountered.
Comments: Placement of a Viabahn stent that high in the venous circuit of an arteriovenous fistula can eliminate options for subsequent access reconstructions if the stent is placed into the central vein. The authors note that placement into the central vein of more than 1 to 3 mm is not desired but emphasizing this fact will help to prevent undesired consequences. It might be better to consider an open patch of the area to improve outflow and preserve the deep veins for subsequent access if any potential compromise of the central vein would result.
Thirty-Day Readmissions After Endovascular or Surgical Therapy for Critical Limb Ischemia: Analysis of the 2013 to 2014 Nationwide Readmissions Databases
Kolte D, Kennedy KF, Shishehbor MH, Abbott JD, Khera S, Soukas P, et al. Circulation 2017; 136:167-76. Conclusions: Approximately 1 in 5 patients hospitalized for critical limb ischemia (CLI) and undergoing revascularization is readmitted within 30 days. Readmission risk is influenced by CLI presentation, patient demographics, comorbidities, and in-hospital complications, but not by the mode of revascularization.
Summary: Thirty-day readmission rates have gained increasing importance as a key quality metric. A significant number of patients are hospitalized for the management of critical limb ischemia (CLI), but limited data are available on the incidence, predictors, and causes of 30-day readmission after the initial hospitalization for CLI. Hospitalizations for a primary diagnosis of CLI during which patients underwent endovascular or surgical therapy (revascularization and/or amputation) and were discharged alive were identified in the 2013 to 2014 Nationwide Readmissions Databases. Incidence, reasons, and costs of 30-day unplanned readmissions were determined. Hierarchical logistic regression models were used to identify independent predictors of 30-day readmissions. Included were 60,998 (national estimate, 135,110) index CLI hospitalizations (mean age, 68.9 6 11.9 years; 40.8% women; 24.6% for rest pain, 37.2% for ulcer, and 38.2% for gangrene). The 30-day readmission rate was 20.4%. Presentation with ulcer or gangrene, age $65 years, female sex, large hospital size, teaching hospital status, known coronary artery disease, heart failure, diabetes mellitus, chronic kidney disease, anemia, coagulopathy, obesity, major bleeding, acute myocardial infarction, vascular complications, and sepsis were identified as independent predictors of 30-day readmission. Mode of revascularization was not independently associated with readmissions. Infections (23.5%), persistent or recurrent manifestations of peripheral artery disease (22.2%), cardiac conditions (11.4%), procedural complications (11.0%), and endocrine issues (5.7%) were the most common reasons for readmission. The inflation-adjusted aggregate costs of 30-day readmissions for CLI during the study period was $624 million.
Comments: These types of studies are always concerning to me because readmissions for planned but delayed minor amputation or debridement may be mislabeled as unplanned and so misrepresent the actual readmission rates. That being said, a rate of 20% is well within the literature reported rate and so is a major concern and expense. It is interesting that an open revascularization was not a risk factor for readmission since long incisions with resulting wound complications are often reported as a significant component of the need for readmissions. It is logical to suggest that these patients require special attention (multidisciplinary) to address the many potential reasons for readmission, but in particular, infection control in consort with the wound care provider, to prevent the need for readmissions.
Incidence of Myocardial Infarction After High-Risk Vascular Operations in Adults
Juo YY, Mantha A, Ebrahimi A, Ziaeian B, Benharash P. JAMA Surg 2017:1-8. doi:10.1001/jamasurg.2017.3360.
Conclusions:
The incidence of myocardial infarction (MI) did not significantly decrease in the past decade and has been consistently associated with worse clinical outcomes. Further inquiry into why advanced perioperative care did not reduce cardiac complications is important to quality patient care.
Summary: Several advances in perioperative cardiac care have been adopted to hopefully improve the outcome of patients requiring vascular operations. To examine the temporal trends of MI following high-risk vascular procedures, this retrospective cohort study was performed using data collected from first of January to 3.1% in 2014; P ¼ .64). Postoperative MI was consistently associated with a poorer prognosis with 3.62-fold increased odds of cardiac arrest and a 3.01-to 6.66-fold increased odds of mortality.
Comments: The presence of a large number of emergency cases, especially in the open aortic cases and in the later years of the study, adds a bias that makes the conclusion questionable. Little advanced perioperative care can be expected in the rupture abdominal aortic patient or even emergent lower extremity bypass; such patients may not have been connected with the health care system to have progressed to this state without prior intervention. The limitations of the NSQIP database including but not limited to lack of specifics on location of cross-clamping in aortic cases and detailed perioperative medical management prevents adequate drill down for cause and effect. The need for a database such as the Vascular Quality Initiative becomes evident to provide such granularity. Conclusions: Hospitalization and long-term costs of carotid artery stenting (CAS) and carotid endarterectomy (CEA) appear similar. Economic considerations should not influence the choice of stenting or surgery in patients with carotid artery stenosis being considered for revascularization.
Meta-Analysis of the Costs of Carotid Artery Stenting and Carotid Endarterectomy
Summary: CAS is currently associated with an increased risk of 30-day stroke compared with CEA, whereas both interventions seem equally durable beyond the periprocedural period. Although the clinical outcomes continue to be scrutinized, there are few data summarizing the costs of both techniques. A systematic search was conducted in MED-LINE, Embase and Cochrane databases in August 2016 identifying articles comparing the costs or cost-effectiveness of CAS and CEA in patients with carotid artery stenosis. The primary endpoints were procedural costs, costs of hospital admission, and cumulative costs during follow-up. The secondary endpoint was health-related quality of life (utility) during follow-up. Combined overall effect sizes were calculated using random-effects models. The in-hospital costs were targeted to gain insight into the main reasons for expenditures associated with both procedures. The literature search identified 617 unique articles, of which five randomized controlled trials (RCTs) and 12 cohort studies were eligible for analysis. A total of 49,419 CAS and 361,699 CEA procedures were identified with a mean patient age 70 years. Sixty three percent were men and 52 % were symptomatic. Although the procedural costs were significantly higher by 51% for CAS (P ¼ .02) mainly driven by device and supplies cost (48% of total in-hospital costs), the length of stay favored CAS (P ¼ .006) resulting in the cost of the index hospital admission similar for CAS and CEA (0.25). The in-hospital stroke rate of patients in the included RCTs was twice as high after CAS than CEA (2.8% vs 1.4%), whereas the in-hospital myocardial rate was twice as high after CEA (3.2% vs 1.5%). Long-term cost analysis revealed no difference in costs or quality of life after one year of follow-up.
Comments: Cost is a component of the quality equation and will become an ever increasing determinate of physician and hospital reimbursement. It appears that CEA or CSA are equally cost competitive at the current time, CAS could realize a cost advantage but only if device and supply costs are decreased to realize that advantage. However, CAS is challenged by an increased risk of perioperative stroke, which is a critical patient quality outcome. Conclusions: The observed reduction of mortality risk from abdominal aortic aneurysm, peripheral arterial disease, and hypertension has never been seen before in the population screening literature and can be linked primarily to initiation of pharmacological therapy. Health policy makers should consider implementing combined screening whether no screening or isolated abdominal aortic aneurysm screening is currently offered.
Population Screening and Intervention for
Summary: Abdominal aortic aneurysm is the only cardiovascular disease targeted by population screening. In this study, the authors test the effect of screening and subsequent intervention for abdominal aortic aneurysm (AAA), peripheral arterial disease (PAD), and hypertension combined. It is a randomized controlled trial randomly allocating (1:1) all men aged 65 to 74 years living in the Central Denmark Region to screening for abdominal aortic aneurysm (> 3 cm), peripheral arterial disease (ankle/brachial index <0.9 or > 1.4), and hypertension (>160 mm Hg systolic or >100 mm Hg diastolic blood pressure), or to no screening. Allocation was by computergenerated random numbers from 1 to 100 in blocks of 1067 to 4392, stratified by 19 municipalities. Only the non-screening group and the investigator assessing outcomes were masked. Participants who were found to have abdominal aortic aneurysm or peripheral arterial disease were invited back for confirmation and eventual initiation of relevant pharmacological therapy. Participants with abdominal aortic aneurysm were offered annual imaging or surgical repair. Participants with suspected hypertension were referred to their general practitioner for treatment. Study patients had a total serum cholesterol concentration measured and if > 4.0 mmol/L were started on statin and aspirin therapy. The primary outcome was all-cause mortality assessed 5 years after randomization. Between October 8, 2008, and January 11, 2011, 50,156 participants were randomly allocated with 25,078 (50%) each in the screening and nonscreening groups. Four (<1%) participants in the screening group were lost to follow-up. There were no differences in baseline characteristics. Interesting, at retest, 11.1% of positive PAD diagnosis were false positives. Thirty-seven percent of patients were started on appropriate medical therapy, while 45.6% were already being treated. Only 32.8% of appropriate patients were motivated to engage in assisted smoking cessation. Of 619 men with AAA, 49.6% had repair within 5 years. After a median follow-up of 4.4 years (IQR, 3.9-4.8 years), 2566 (10.2%) of 25,074 participants in the screening group and 2715 (10.8%) of 25,078 in the non-screening group had died. This finding resulted in a significant hazard ratio of 0.93 (95% confidence interval [CI], 0.88-0.98; P ¼ .01), an absolute risk reduction of 0.006 (95% CI, 0.001-0.011), and a number needed to invite to screening to save one life was 169 (95% CI, 89-1811). Incidences of diabetes (3995 per 100 000 person-years in the screening group vs 4129 per 100,000 person-years in the nonscreening group), intracerebral hemorrhage (146 vs 140), renal failure (612 vs 649), cancer (3578 vs 3719), or 30 day mortality after cardiovascular surgery (44.57 vs 39.33) did not differ between groups.
Comments: A commentary to this article published in Lancet from Mayo is an excellent read and highlights my concerns with this article.
1 This article bundles two screening interventions known to be effective (abdominal aortic aneurysm and hypertension screening) with ankle/brachial index screening which currently has not be shown to be effective. Legitimizing ABI screening in this manner may place asymptomatic patients at risk if invasive intervention is the response. Furthermore, the cost of screening in the asymptomatic population where only w 10% of patients were found to have an abnormal ABI may not be cost ineffective. Remember, screening program should be accurate, not harmful (downstream testing, treatment, procedures, complications), and cost-effective among other requirements. Reference 1. Population-based screening for vascular disease. Ayoub C, Murad MH. Lancet 2017:1-2. https://doi.org/10.1016/S0140-6736(17)32250-X.
